MHRA
Safeguarding public health

Medicines and Healthcare products Regulatory Agency

Market Towers
1 Nine Elms Lane, London SW8 5NQ

Direct Line: 020 7084-2456
Facsimile: 020 7084-2443
Room: 12- 242

CTA number: 20363/0204/001-0001
EudraCT number: 2004-002197-34

Cathy H. Burton
Cancer Research UK &
UCL Cancer Trials Centre
Lymphoma Trials Office
222 Euston Road
NW1 2DA

8 August 2005

Dear Ms Burton

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 1031

Product: Rituximab
Protocol number: 04/Q1104/27

ACKNOWLEDGEMENT OF AMENDMENT

Thank you for your request received on 5 August 2005 for an amendment to the above Clinical Trial Authorisation (CTA) under the above Regulations.

The information you provided to support your request is complete and therefore your request is valid.

It is the Authority's intention within 35 days of the date of receipt of the request, to notify you, where appropriate, by either setting out the grounds for not accepting the proposed amendment or accepting the application for amendment with or without conditions. If you are not sent either notice then the amendment can be made.

If you have any queries about this letter please do not hesitate to contact me.

Yours sincerely

Dr Martyn Ward
Head of Clinical Trials Unit